Search results
Results from the WOW.Com Content Network
The Vaccine Adverse Event Reporting System (VAERS) is a United States program for vaccine safety, co-managed by the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). [1]
The Vaccine Adverse Event Reporting System (VAERS) is a passive surveillance program administered jointly by the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). [38] VAERS is intended to track adverse events associated with vaccines.
The NCVIA also mandates that all health care providers must report certain adverse events following vaccination to the Vaccine Adverse Event Reporting System (VAERS). [citation needed] The NCVIA also established a committee from the Institute of Medicine (IOM) to review the existing literature on vaccine adverse events occurring after immunization.
The VICP was adopted in response to concerns over the pertussis portion of the DPT vaccine. [1] Several U.S. lawsuits against vaccine makers won substantial awards. Most makers ceased production, and the last remaining major manufacturer threatened to do so. [1] The VICP uses a no-fault system for resolving vaccine injury claims. [1]
The FDA Adverse Event Reporting System (FAERS or AERS) is a computerized information database designed to support the U.S. Food and Drug Administration's (FDA) postmarketing safety surveillance program for all approved drug and therapeutic biologic products.
The ACIP was established in March 1964 by the US Surgeon General to assist in the prevention and control of communicable diseases, [2] it recommends licensed new vaccines to be incorporated into the routine immunization schedule, recommends vaccine formulations, and reviews older vaccines to consider revising its recommendations.
Current events; Random article; ... 4 Number of Adverse Events reported each year. 7 comments. Toggle the table of contents. Talk: Vaccine Adverse Event Reporting ...
Until a vaccine is in use amongst the general population, all potential adverse events from the vaccine may not be known, requiring manufacturers to conduct Phase IV studies for postmarketing surveillance of the vaccine while it is used widely in the public. [103] [109] The WHO works with UN member states to implement post-licensing ...